The group

For the past 40 years, the DiaSorin Group has been an international player in the market for in vitro diagnostics, a specific segment of immunodiagnostics that encompasses the categories of immunochemistry and infectious immunology. The expression “in vitro” designates the market for diagnostic products used to test samples taken from patients (blood, urine, etc.), as separate from in vivo, or injectable, products, which are administered to patients directly.

The products developed and distributed by the DiaSorin Group are designed specifically for clinical diagnostics applications. They are used by diagnostic laboratories that are part of hospital facilities or operate independently (private diagnostic services laboratories). For the most part, they help physicians in diagnosing different diseases (diagnostic benefit), determining the progress of a disease (prognostic benefit) and assessing the effectiveness of a drug treatment (monitoring benefit).

The Group is comprised of 24 companies located in Europe, the United States, Central and South America, Asia and South Africa, with almost 1,500 employees, 110 of whom work exclusively on research and development projects (data updated at 06/310).
Production is carried out at six manufacturing and research facilities located in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater, MN (USA), Dublin (Ireland), Dartford(UK) and Kyalami (South Africa).

DiaSorin is present in more than 60 countries with its direct sales network, supported by an international network of almost 80 independent distributors.